Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gal-geun-dang-gwi-tang (GGDGT) is a traditional Korean herbal medicine used clinically to treat hypertension, stroke, diabetes, and other inflammatory vascular disorders. In animal models of diabetic atherosclerosis, GGDGT has demonstrated improvement of glucose tolerance, lipid levels, and endothelial dysfunction. Mechanistically, it attenuates vascular inflammation by suppressing the expression of adhesion molecules such as ICAM-1, VCAM-1, and E-selectin. GGDGT also restores endothelial nitric oxide synthase (eNOS) and insulin receptor substrate-1 (IRS-1) expression, suggesting action through the nitric oxide (NO)-cyclic guanosine monophosphate signaling pathway and improvement of insulin sensitivity in diabetic complications[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gal-geun-dang-gwi-tang.